Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Progression Free Survival of Relapsed or Refractory Multiple Myeloma (RRMM) after Failure of Three Prior Lines of Therapy in United States (US) Real-World Practice

Christopher Kim, PhD, Megan Braunlin, MPH, Rajesh Belani, MD, John Travis Wheeling, MPH

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-140549

Published: 2020

Journal Articles

Trends in the Multiple Myeloma Treatment Landscape: A United States Analysis of Oscer Electronic Health Record Data 2011-2019

Megan Braunlin, MPH, Rajesh Belani, MD, Jacqueline Buchanan, John Travis Wheeling, MPH, Christopher Kim, PhD

Blood (2019) 134 (Supplement_1): 4722.

https://doi.org/10.1182/blood-2019-125972

Published: 2019

Journal Articles

Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia

Farhad Ravandi, MD, Sherry A. Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Elias J. Jabbour, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD MSc, Naval G. Daver, MD, Nicholas J Short, MD, Yesid Alvarado, MD, Jorge E. Cortes, MD, Christopher Kim, PhD, Michael A Kelsh, PhD MPH, MA, Aaron Jacob Katz, PhD PharmD, Richard Williams, MBBS, PhD, Zhao Yang, Bhakti Mehta, MD MPH, Hagop M. Kantarjian, MD

Blood (2018) 132 (Supplement 1): 3985.

https://doi.org/10.1182/blood-2018-99-118380

Published: 2018

Journal Articles

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Shaji K. Kumar, MD, Alan Fu, PhD MPH, Khalid Mezzi, Megan Braunlin, Christopher Kim, PhD, Karim Iskander, Ruben Niesvizky, MD, Sundar Jagannath, MD, Ralph Boccia, MD, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 3253.

https://doi.org/10.1182/blood-2018-99-113519

Published: 2018

Journal Articles

Trends in Neutropenia-Related Hospitalization in Older Patients with Non-Hodgkin Lymphoma (NHL) Receiving Myelosuppressive Chemotherapy in the United States: 1995-2015

Shuling Li, PhD, Jiannong Liu, PhD, Haifeng Guo, MS, Prasad L Gawade, MBBS, PhD, Christopher Kim, PhD, Mark E. Bensink, PhD MSc, MD, David Chandler, PhD

Blood (2018) 132 (Supplement 1): 2308.

https://doi.org/10.1182/blood-2018-99-115213

Published: 2018

Journal Articles

Treatment, HSCT Patterns, and Survival of Elderly Diffuse Large B-Cell Lymphoma Patients in the SEER-Medicare Linked Database

Jaime Shaw, MPH, Lauren Johns, PhD, Christopher Harvey, MS, Catherine Richards, PhD, Christopher Kim, PhD

Blood (2018) 132 (Supplement 1): 3584.

https://doi.org/10.1182/blood-2018-99-111051

Published: 2018

Journal Articles

Demographic and Clinical Characteristics of Multiple Myeloma (MM) Patients Treated with Carfilzomib-Based Regimens in a Real World Setting

Christopher Kim, PhD, Winifred Werther, Karim Saad Iskander, Michael Gruber, Khalid Mezzi, MD MBA

Blood (2017) 130 (Supplement 1): 5441.

https://doi.org/10.1182/blood.V130.Suppl_1.5441.5441

Published: 2017

Journal Articles

Multiple Myeloma Patients and Risk of Skeletal Related Events - Real-World Evidence in US Oncology Clinics

Sumita Bhatta, MD, Lori Cyprien, Rafael Fonseca, MD, Rohini K Hernandez, PhD, Christopher Kim, PhD

Blood (2017) 130 (Supplement 1): 2171.

https://doi.org/10.1182/blood.V130.Suppl_1.2171.2171

Published: 2017

Journal Articles

Cross-Sectional Physician Survey on the Use of Minimal Residual Disease (MRD) Testing in the Management of Pediatric and Adult Patients with Acute Lymphoblastic Leukemia (ALL)

Victoria M Chia, PhD MPH, Kara Delaney, BS, Michelle McNamara, Bsc, Christopher Kim, PhD, Vadim Romanov, MD Mphil, FFPM

Blood (2017) 130 (Supplement 1): 5120.

https://doi.org/10.1182/blood.V130.Suppl_1.5120.5120

Published: 2017

Journal Articles

Efficacy and Safety of Darbepoetin Alfa (DA) in Patients with Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis

Sophie Park, MD PhD, Pierre Fenaux, MD PhD, Peter Greenberg, MD, Bhakti Mehta, MD MPH, Fiona Callaghan, PhD, Christopher Kim, PhD MPH, Dianne Tomita, PhD, Hairong Xu, MD PhD

Blood (2015) 126 (23): 5236.

https://doi.org/10.1182/blood.V126.23.5236.5236

Published: 2015

NARROW

Progression Free Survival of Relapsed or Refractory Multiple Myeloma (RRMM) after Failure of Three Prior Lines of Therapy in United States (US) Real-World Practice

Trends in the Multiple Myeloma Treatment Landscape: A United States Analysis of Oscer Electronic Health Record Data 2011-2019

Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Trends in Neutropenia-Related Hospitalization in Older Patients with Non-Hodgkin Lymphoma (NHL) Receiving Myelosuppressive Chemotherapy in the United States: 1995-2015

Treatment, HSCT Patterns, and Survival of Elderly Diffuse Large B-Cell Lymphoma Patients in the SEER-Medicare Linked Database

Demographic and Clinical Characteristics of Multiple Myeloma (MM) Patients Treated with Carfilzomib-Based Regimens in a Real World Setting

Multiple Myeloma Patients and Risk of Skeletal Related Events - Real-World Evidence in US Oncology Clinics

Cross-Sectional Physician Survey on the Use of Minimal Residual Disease (MRD) Testing in the Management of Pediatric and Adult Patients with Acute Lymphoblastic Leukemia (ALL)

Efficacy and Safety of Darbepoetin Alfa (DA) in Patients with Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only